{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:58:58Z","timestamp":1793105938019,"version":"4.5.0"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"\n Importance<\/jats:title>\n Data from 2 phase 3 studies of gantenerumab, GRADUATE I\/II, and their open-label extensions represent a resource to further characterize amyloid-related imaging abnormalities (ARIA), including long-term sequelae.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To describe the characteristics of ARIA and risk factors and clinical consequences of ARIA-edema (ARIA-E).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Secondary data collection from the GRADUATE I\/II phase 3 randomized, double-blind, placebo-controlled, 116-week parallel-group studies and their open-label extensions, including PostGraduate, with up to 210 (mean, 125) weeks of total gantenerumab treatment were conducted between 2018 and 2023. The study included multicenter trials at 288 sites across 30 countries. GRADUATE I\/II enrolled 985 and 980 participants, respectively, with early symptomatic Alzheimer disease (AD) and amyloid-beta (A\u03b2) pathology who were aged 50 to 90 years. PostGraduate enrolled 1382 participants (671 previously randomized to gantenerumab). Data were analyzed from November 2, 2022, to October 10, 2023.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n GRADUATE I\/II participants were randomized 1:1 to gantenerumab or placebo. Nine-month uptitration was used to mitigate ARIA risk.<\/jats:p>\n <\/jats:sec>\n \n Main outcomes and measures<\/jats:title>\n Postbaseline safety monitoring, including brain magnetic resonance imaging (MRI) findings, and adverse events and cognitive assessments.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The safety-evaluable MRI population of GRADUATE I\/II comprised 1939 participants (mean age, 71.7 years; 1105 female [57.0%]). Severity of AD\u2013related A\u03b2 neuropathology (lower cerebrospinal fluid [CSF] A\u03b242, hazard ratio [HR] for CSF A\u03b242: 0.4; 95% CI, 0.2-0.7) and comorbid cerebrovascular pathology (Fazekas score: HR, 1.6; 95% CI, 1.3-2.0; total superficial siderosis count: HR, 1.9; 95% CI, 1.3-2.6; total microhemorrhage count: HR, 1.3; 95% CI, 1.0-1.5) may be important baseline risk factors for ARIA-E, in addition to apolipoprotein E (APOE) \u03b54 status (APOE \u03b54 heterozygous carrier: HR, 2.0; 95% CI, 1.4-2.8 and APOE \u03b54 homozygous carrier: HR, 4.7; 95% CI, 3.2-6.7). At the group level, ARIA-E did not impact long-term cognitive and functional performance (relative difference in adjusted means for Clinical Dementia Rating\u2013Sum of Boxes was \u22129% in pooled GRADUATE analysis at week 116 and when censored at first ARIA-E). While taking gantenerumab, ARIA-E and ARIA-hemosiderin occurred in 24.9% (247 of 993) and 22.9% (227 of 993) participants, respectively; first ARIA-E occurred by week 64 in 86.2% (213 of 247) of participants with ARIA-E. Narratives are provided for all serious symptomatic ARIA-E cases.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n These results show that in addition to APOE \u03b54 allele count, severity of A\u03b2 neuropathology and comorbid cerebrovascular pathology may be relevant for clinicians prescribing anti-A\u03b2 monoclonal antibodies for early AD and developing individualized safety monitoring plans. Evaluation of these risk factors in other anti-A\u03b2 monoclonal antibodies is recommended.<\/jats:p>\n <\/jats:sec>\n \n Trial registrations<\/jats:title>\n \n ClinicalTrials.gov Identifiers:\n NCT03444870<\/jats:ext-link>\n ,\n NCT03443973<\/jats:ext-link>\n ,\n NCT04374253<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.3937","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T11:32:24Z","timestamp":1731929544000},"page":"19","source":"Crossref","is-referenced-by-count":63,"title":["Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease"],"prefix":"10.1001","volume":"82","author":[{"given":"Stephen","family":"Salloway","sequence":"first","affiliation":[{"name":"Warren Alpert Medical School, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Wojtowicz","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Voyle","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Lane","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Klein","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lyons","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Rossomanno","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mazzo","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szofia","family":"Bullain","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"},{"name":"Biogen International GmbH, Baar, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Vrije Universiteit, Amsterdam UMC, Amsterdam, the Netherlands"},{"name":"Queen Square Institute of Neurology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bittner","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"},{"name":"Genentech, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Schneider","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grundman","sequence":"additional","affiliation":[{"name":"Global R&D Partners, LLC, and Dept. of Neurosciences, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Aldea","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[{"name":"Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain"},{"name":"Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Smith","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Doody","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"},{"name":"Genentech, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"noi240070r1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years.","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"6","key":"noi240070r2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"noi240070r3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"noi240070r4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1001\/jama.2023.11701","article-title":"Ushering in a new era of Alzheimer disease therapy.","volume":"330","author":"Widera","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"noi240070r7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup.","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"11","key":"noi240070r8","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"24","key":"noi240070r9","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"noi240070r10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis.","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"issue":"1","key":"noi240070r11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease.","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"noi240070r12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease\u2014one peptide, two pathways.","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"noi240070r13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease.","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"issue":"19","key":"noi240070r14","doi-asserted-by":"publisher","first-page":"e2092","DOI":"10.1212\/WNL.0000000000201019","article-title":"Incidence of amyloid-related imaging abnormalities in patients with Alzheimer disease treated with anti-\u00df-amyloid immunotherapy: a meta-analysis.","volume":"99","author":"Jeong","year":"2022","journal-title":"Neurology"},{"key":"noi240070r15","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12377","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer\u2019s disease.","author":"Honig","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"noi240070r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110020","article-title":"Microglia and TREM2.","volume":"257","author":"Pocock","year":"2024","journal-title":"Neuropharmacology"},{"key":"noi240070r17","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12306","article-title":"In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.","author":"Aldea","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"noi240070r18","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/ijms25020817","article-title":"The importance of complement-mediated immune signaling in Alzheimer\u2019s disease pathogenesis.","volume":"25","author":"Batista","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"20","key":"noi240070r22","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease.","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"noi240070r24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/cpt.2535","article-title":"Disease modeling and model-based meta-analyses to define a new direction for a phase III program of gantenerumab in Alzheimer\u2019s disease.","volume":"111","author":"Retout","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"noi240070r25","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3174\/ajnr.A3475","article-title":"An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion.","volume":"34","author":"Barkhof","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"noi240070r26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jamaneurol.2021.3933","article-title":"Six recurrent amyloid-related imaging abnormality episodes in a patient treated with aducanumab.","volume":"79","author":"Hall","year":"2022","journal-title":"JAMA Neurol"},{"issue":"3","key":"noi240070r27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and \u00df-amyloid-targeting antibodies: a systematic review.","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"noi240070r28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease.","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"noi240070r29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jalz.2011.05.2353","article-title":"Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer\u2019s disease study cohorts from phase 3 trials of semagacestat and solanezumab.","volume":"7","author":"Carlson","year":"2011","journal-title":"Alzheimers Dement"},{"key":"noi240070r30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3389\/fneur.2015.00207","article-title":"Anti-A\u00df autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer\u2019s disease and cerebral amyloid angiopathy.","volume":"6","author":"DiFrancesco","year":"2015","journal-title":"Front Neurol"},{"issue":"25","key":"noi240070r31","doi-asserted-by":"publisher","first-page":"39941","DOI":"10.18632\/oncotarget.17990","article-title":"APOE genotype and Alzheimer\u2019s immunotherapy.","volume":"8","author":"Pankiewicz","year":"2017","journal-title":"Oncotarget"},{"issue":"S10","key":"noi240070r32","doi-asserted-by":"publisher","DOI":"10.1002\/alz.065856","article-title":"Baseline risk factors for developing ARIA-E from the SCarlet RoAD and Marguerite RoAD open-label extension studies.","volume":"18","author":"Lyons","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi240070r33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207919","article-title":"Genome-wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE studies.","volume":"102","author":"Loomis","year":"2024","journal-title":"Neurology"},{"issue":"4","key":"noi240070r34","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","article-title":"CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.","volume":"60","author":"Strozyk","year":"2003","journal-title":"Neurology"},{"key":"noi240070r35","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1412006","article-title":"Three major effects of APOEe4 on A\u00df immunotherapy induced ARIA.","volume":"16","author":"Foley","year":"2024","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"noi240070r36","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","article-title":"The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study.","volume":"21","author":"Charidimou","year":"2022","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi240070r37","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jalz.2016.09.006","article-title":"Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study.","volume":"13","author":"Wardlaw","year":"2017","journal-title":"Alzheimers Dement"},{"key":"noi240070r39","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-240221","article-title":"Long-term safety of gantenerumab in participants with Alzheimer\u2019s disease: a phase III, double-blind, and open-label extension study (Marguerite RoAD).","author":"Neve","year":"2024","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"4","key":"noi240070r40","doi-asserted-by":"publisher","first-page":"765","DOI":"10.14283\/jpad.2023.96","article-title":"Initial experiences with amyloid-related imaging abnormalities in patients receiving aducanumab following accelerated approval.","volume":"10","author":"Howe","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"noi240070r41","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12376","article-title":"Comparing ARIA-E severity scales and effects of treatment management thresholds.","volume":"14","author":"Klein","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"noi240070r42","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttl amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans.","volume":"15","author":"Grimm","year":"2023","journal-title":"MAbs"},{"key":"noi240070r23","author":"Hutmacher","year":"2013"},{"key":"noi240070r43","author":"Kulic","year":"2024"},{"key":"noi240070r5","unstructured":"Eisai. LEQEMBI prescribing information. Accessed October 15, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269Orig1s001lbl.pdf"},{"key":"noi240070r6","unstructured":"Eli Lilly. KISUNLA (donanemab-azbt) prescribing information. Accessed October 15, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf"},{"key":"noi240070r19","unstructured":"ClinicalTrials.gov. Efficacy and safety study of gantenerumab in participants with early Alzheimer\u2019s disease (AD). Accessed October 15, 2024. https:\/\/clinicaltrials.gov\/study\/NCT03444870"},{"key":"noi240070r20","unstructured":"ClinicalTrials.gov. Safety and efficacy study of gantenerumab in participants with early Alzheimer\u2019s disease (AD). Accessed October 15, 2024. https:\/\/clinicaltrials.gov\/study\/NCT03443973"},{"key":"noi240070r21","unstructured":"ClinicalTrials.gov. A study to evaluate the safety, tolerability, and efficacy of long-term gantenerumab administration in participants with Alzheimer\u2019s disease (AD). Accessed October 15, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04374253"},{"key":"noi240070r38","unstructured":"Biogen. ADUHELM (aducanumab-avwa) prescribing information. Accessed October 15, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761178s011lbl.pdf"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2826606\/jamaneurology_salloway_2024_oi_240070_1741031410.7801.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T15:00:25Z","timestamp":1741014025000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2826606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.3937","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}